Clinical Trials Directory

Trials / Completed

CompletedNCT00213148

Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

A Phase II, Prospective, Randomized, Double-Blind, Multicenter, Dose Finding, Comparative Study for the Evaluation of the Aromatase Inhibitor Anastrozole (Multiple-Dose) Versus Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
271 (actual)
Sponsor
EMD Serono · Industry
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate and compare the safety and efficacy of various doses of the aromatase inhibitor (anastrozole) versus clomiphene citrate in stimulating follicular growth and ovulation in infertile women with ovulatory dysfunction.

Conditions

Interventions

TypeNameDescription
DRUGAnastrozole 1 mgSubjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
DRUGAnastrozole 5 mgSubjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
DRUGAnastrozole 10 mgSubjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
DRUGClomiphene Citrate 50 mgSubjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
DRUGClomiphene Citrate 100 mgSubjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).

Timeline

Start date
2005-03-10
Primary completion
2007-12-12
Completion
2007-12-12
First posted
2005-09-21
Last updated
2018-07-17
Results posted
2018-07-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00213148. Inclusion in this directory is not an endorsement.